Epstein Secrets

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for Ix Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop

aragraph IV challenge is set for 9/26/16, with a potential ruling in 1Q17; the lower court case is consolidated for all known generic filers, i.e., MNTA/Sandoz, Mylan, Dr. Reddy's, Synthon/Pfizer and Amneal. We note that both the IPR decision and the lower court ruling can be appealed. Amanda Ens EFTA0082

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mrn/yr in sales for Co

aragraph IV challenge is set for 9/26/16, with a potential ruling in 1Q17; the lower court case is consolidated for all known generic filers, i.e., MNTA/Sandoz, Mylan, Dr. Reddy's, Synthon/Pfizer and Amneal. We note that both the IPR decision and the lower court ruling can be appealed. EFTA00820351 Amand

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop

Paragraph IV challenge is set for 9/26/16, with a potential ruling in 1Q17; the lower court case is consolidated for all known generic filers, i.e., MNTA/Sandoz, Mylan, Dr. Reddy's, Synthon/Pfizer and Amneal. We note that both the IPR decision and the lower court ruling can be appealed. Amanda Ens Director